- Talanx’s net income for the first quarter stands at EU 572 million.
- The company’s Ebit also reaches EU 1.22 billion.
- The property and casualty combined ratio is reported at 90.9%.
- Talanx maintains its year-end forecast of a net income above EU 1.70 billion.
- Estimations predict a net income of around EU 1.85 billion by the end of the year.
- The company expresses increased confidence in significantly surpassing the EU 1.7 billion net income mark.
- Current analyst consensus stands at 2 buys, 6 holds, and 2 sell recommendations for Talanx.
A look at Talanx Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts at Smartkarma have assessed Talanx, a holding company providing insurance and financial services, using their Smart Scores system. Based on the scores assigned, Talanx shows promising long-term potential. With strong scores in Dividend (4), Growth (4), and Momentum (4), the company is positioned well for future development and value creation. This suggests that Talanx may offer stability and growth opportunities for investors seeking dividends and capital appreciation.
Talanx’s overall outlook, as indicated by the Smart Scores, reflects a company with robust fundamentals and growth potential. While Value and Resilience scores are slightly lower at 3, the positive scores in key areas signal a competitive position in the insurance and financial services industry. With a global presence offering various insurance products and related services, Talanx seems well-equipped to navigate market challenges and capitalize on growth opportunities in the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
